Abstract
One of the most recent major advances in vaccinology, and currently the only licensed alternative to the traditional alum-based adjuvants, are immunopotentiating reconstituted influenza virosomes. The flexibility of this novel antigen delivery system enables the safe and effective delivery of modern vaccine developments, such as viral glycoproteins, bacterial toxoids, inactivated virus, recombinant proteins, synthetic peptides and DNA-plasmids or polynucleotides. These novel vaccine antigens are being incorporated into immunopotentiating reconstituted influenza virosomes in an attempt to develop a variety of new viral, bacterial and parasitic vaccines. In addition, immunopotentiating reconstituted influenza virosomes are showing future potential in the targeting of specific cells, such as tumor cells, and novel routes of vaccine administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
